메뉴 건너뛰기




Volumn 67, Issue 1, 2014, Pages 36-44

Use of expert consensus to improve atherogenic dyslipidemia management;Consenso de expertos sobre propuestas para la mejora del manejo de la dislipemia aterogénica

Author keywords

Atherogenic dyslipidemia; Cardiovascular risk; Consensus; Delphi

Indexed keywords

ARTICLE; ATHEROGENIC DYSLIPIDEMIA; DYSLIPIDEMIA; FOLLOW UP; HUMAN; MEDICAL SPECIALIST; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CONSENSUS; DELPHI STUDY; DYSLIPIDEMIAS; EVIDENCE BASED MEDICINE; PRACTICE GUIDELINE; PROCEDURES; RISK FACTOR;

EID: 84891828770     PISSN: 03008932     EISSN: 15792242     Source Type: Journal    
DOI: 10.1016/j.recesp.2013.06.014     Document Type: Article
Times cited : (22)

References (24)
  • 1
    • 84863092194 scopus 로고    scopus 로고
    • European guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts)
    • J. Perk, G. De Backer, H. Gohlke, I. Graham, Z. Reiner, and W.M. Verschuren et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) Atherosclerosis 223 2012 1 68
    • (2012) Atherosclerosis , vol.223 , pp. 1-68
    • Perk, J.1    De Backer, G.2    Gohlke, H.3    Graham, I.4    Reiner, Z.5    Verschuren, W.M.6
  • 2
    • 79960205374 scopus 로고    scopus 로고
    • The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)
    • ESC/EAS Guidelines for the management of dyslipidaemias
    • A.L. Catapano, Z. Reiner, G. De Backer, I. Graham, M.R. Taskinen, O. Wiklund ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) Atherosclerosis 217 2011 3 46
    • (2011) Atherosclerosis , vol.217 , pp. 3-46
    • Catapano, A.L.1    Reiner, Z.2    De Backer, G.3    Graham, I.4    Taskinen, M.R.5    Wiklund, O.6
  • 3
    • 41549118416 scopus 로고    scopus 로고
    • Lipoprotein management in patients with cardiometabolic risk: Consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation
    • J.D. Brunzell, M. Davidson, C.D. Furberg, R.B. Goldberg, B.V. Howard, and J.H. Stein et al. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation J Am Coll Cardiol 51 2008 1512 1524
    • (2008) J Am Coll Cardiol , vol.51 , pp. 1512-1524
    • Brunzell, J.D.1    Davidson, M.2    Furberg, C.D.3    Goldberg, R.B.4    Howard, B.V.5    Stein, J.H.6
  • 4
    • 77953870172 scopus 로고    scopus 로고
    • Riesgo vascular residual: Recomendaciones de la Iniciativa Española para la Reducción del Riesgo Residual
    • J. Millán Núñez-Cortés, J. Pedro-Botet Montoya, and X. Pintó Sala Riesgo vascular residual: recomendaciones de la Iniciativa Española para la Reducción del Riesgo Residual Med Clin (Barc) 135 2010 165 171
    • (2010) Med Clin (Barc) , vol.135 , pp. 165-171
    • Millán Núñez-Cortés, J.1    Pedro-Botet Montoya, J.2    Pintó Sala, X.3
  • 9
    • 85045797561 scopus 로고    scopus 로고
    • Literature searching for clinical and cost-effectiveness studies used in health technology assessment reports carried out for the National Institute for Clinical Excellence appraisal system
    • P. Royle, and N. Waugh Literature searching for clinical and cost-effectiveness studies used in health technology assessment reports carried out for the National Institute for Clinical Excellence appraisal system Health Technol Assess 7 2003 1 51
    • (2003) Health Technol Assess , vol.7 , pp. 1-51
    • Royle, P.1    Waugh, N.2
  • 10
    • 0001345835 scopus 로고
    • Snowball sampling
    • L.A. Goodman Snowball sampling Ann Math Stat 32 1961 148 170
    • (1961) Ann Math Stat , vol.32 , pp. 148-170
    • Goodman, L.A.1
  • 11
    • 38749140256 scopus 로고    scopus 로고
    • An exploration of the use of simple statistics to measure consensus and stability in Delphi studies
    • E.A. Holey, J.L. Feeley, J. Dixon, and V.J. Whittaker An exploration of the use of simple statistics to measure consensus and stability in Delphi studies BMC Med Res Methodol 7 2007 52
    • (2007) BMC Med Res Methodol , vol.7 , pp. 52
    • Holey, E.A.1    Feeley, J.L.2    Dixon, J.3    Whittaker, V.J.4
  • 12
    • 79958148945 scopus 로고    scopus 로고
    • Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: Evidence and guidance for management
    • M.J. Chapman, H.N. Ginsberg, P. Amarenco, F. Andreotti, J. Borén, and A.L. Catapano et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management Eur Heart J 32 2011 1345 1361
    • (2011) Eur Heart J , vol.32 , pp. 1345-1361
    • Chapman, M.J.1    Ginsberg, H.N.2    Amarenco, P.3    Andreotti, F.4    Borén, J.5    Catapano, A.L.6
  • 13
    • 0026065576 scopus 로고
    • Plasma triglyceride and coronary heart disease
    • M.A. Austin Plasma triglyceride and coronary heart disease Arterioscler Thromb 11 1991 2 14
    • (1991) Arterioscler Thromb , vol.11 , pp. 2-14
    • Austin, M.A.1
  • 14
    • 0029838433 scopus 로고    scopus 로고
    • Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: A meta-analysis of population-based prospective studies
    • J.E. Hokanson, and M.A. Austin Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies J Cardiovasc Risk 3 1996 213 219
    • (1996) J Cardiovasc Risk , vol.3 , pp. 213-219
    • Hokanson, J.E.1    Austin, M.A.2
  • 15
    • 56149115017 scopus 로고    scopus 로고
    • Nonfasting triglycerides and risk of ischemic stroke in the general population
    • J.J. Freiber, A. Tybjaerg-Hansen, J.S. Jensen, and B.G. Nordestgard Nonfasting triglycerides and risk of ischemic stroke in the general population JAMA 300 2008 2142 2152
    • (2008) JAMA , vol.300 , pp. 2142-2152
    • Freiber, J.J.1    Tybjaerg-Hansen, A.2    Jensen, J.S.3    Nordestgard, B.G.4
  • 17
    • 70450081001 scopus 로고    scopus 로고
    • Major lipids, apolipoproteins, and risk of vascular disease
    • The Emerging Risk Factor Collaboration
    • The Emerging Risk Factor Collaboration Major lipids, apolipoproteins, and risk of vascular disease JAMA 302 2009 1993 2000
    • (2009) JAMA , vol.302 , pp. 1993-2000
  • 18
    • 34748887666 scopus 로고    scopus 로고
    • HDL cholesterol, very low levels of LDL cholesterol and cardiovascular events
    • Treating to New targets Investigators
    • P. Barter, A.M. Gotto, J.C. LaRosa, J. Maroni, M. Szarek, S.M. Grundy Treating to New targets Investigators HDL cholesterol, very low levels of LDL cholesterol and cardiovascular events N Engl J Med 357 2007 1301 1310
    • (2007) N Engl J Med , vol.357 , pp. 1301-1310
    • Barter, P.1    Gotto, A.M.2    Larosa, J.C.3    Maroni, J.4    Szarek, M.5    Grundy, S.M.6
  • 19
    • 78449281377 scopus 로고    scopus 로고
    • Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170 000 participants in 26 randomized trials
    • Cholesterol Treatment Trialist's CTT Collaboration
    • Cholesterol Treatment Trialist's CTT Collaboration Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomized trials Lancet 376 2010 1670 1681
    • (2010) Lancet , vol.376 , pp. 1670-1681
  • 20
    • 33750897238 scopus 로고    scopus 로고
    • Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug subclasses, and their combinations: A meta-analysis of 23 ramdomized lipid trials
    • B.G. Brown, K.H. Stukowsky, and X.Q. Zhao Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug subclasses, and their combinations: a meta-analysis of 23 ramdomized lipid trials Curr Opin Lipidol 17 2006 631 636
    • (2006) Curr Opin Lipidol , vol.17 , pp. 631-636
    • Brown, B.G.1    Stukowsky, K.H.2    Zhao, X.Q.3
  • 21
    • 85048354213 scopus 로고    scopus 로고
    • Combination lipid therapy in type 2 diabetes
    • F.M. Sacks, V.J. Carey, and J.C. Fruchart Combination lipid therapy in type 2 diabetes N Engl J Med 363 2010 692 694
    • (2010) N Engl J Med , vol.363 , pp. 692-694
    • Sacks, F.M.1    Carey, V.J.2    Fruchart, J.C.3
  • 22
    • 64749095070 scopus 로고    scopus 로고
    • Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
    • Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators
    • R. Scott, R. O'Brien, G. Fulcher, C. Pardy, M. D'Emden, D. Tse Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study Diabetes Care 32 2009 493 498
    • (2009) Diabetes Care , vol.32 , pp. 493-498
    • Scott, R.1    O'Brien, R.2    Fulcher, G.3    Pardy, C.4    D'Emden, M.5    Tse, D.6
  • 23
    • 77951704587 scopus 로고    scopus 로고
    • Effects of combination lipid therapy in type 2 diabetes mellitus
    • ACCORD Study Group
    • H.N. Ginsberg, M.B. Elam, L.C. Lovato, J.R. Crouse, L.A. Leiter, P. Linz ACCORD Study Group Effects of combination lipid therapy in type 2 diabetes mellitus N Engl J Med 362 2010 1563 1574
    • (2010) N Engl J Med , vol.362 , pp. 1563-1574
    • Ginsberg, H.N.1    Elam, M.B.2    Lovato, L.C.3    Crouse, J.R.4    Leiter, L.A.5    Linz, P.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.